BeOne Medicines (NASDAQ:ONC) Stock Price Down 4.8% – What’s Next?

05 Dec 2025, 14:16 by Doug Wharley · The Cerbat Gem

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report)’s stock price dropped 4.8% on Friday . The stock traded as low as $312.44 and last traded at $315.56. Approximately 190,761 shares traded hands during trading, a decline of 50% from the average daily volume of 384,078 shares. The stock had previously closed at $331.40.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on ONC shares. JPMorgan Chase & Co. raised their target price on shares of BeOne Medicines from $345.00 to $385.00 and gave the company an “overweight” rating in a research note on Wednesday, October 8th. Wall Street Zen upgraded BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Friday, October 3rd. Citizens Jmp lifted their target price on BeOne Medicines from $348.00 to $396.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Citigroup upped their price target on shares of BeOne Medicines from $399.00 to $405.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Finally, Truist Financial set a $400.00 price target on shares of BeOne Medicines in a research report on Monday, November 24th. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $365.79.

Read Our Latest Analysis on ONC

BeOne Medicines Trading Down 3.9%

The company has a market capitalization of $37.76 billion, a price-to-earnings ratio of 624.59 and a beta of 0.45. The firm has a fifty day moving average price of $332.91 and a 200-day moving average price of $301.64. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.17 and a current ratio of 2.39.

Insider Buying and Selling

In other news, COO Xiaobin Wu sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $356.02, for a total transaction of $3,560,200.00. Following the completion of the sale, the chief operating officer owned 6,009 shares of the company’s stock, valued at approximately $2,139,324.18. This represents a 62.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Lai Wang sold 5,000 shares of the company’s stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $350.06, for a total value of $1,750,300.00. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 81,094 shares of company stock worth $27,929,161. 6.62% of the stock is owned by company insiders.

Hedge Funds Weigh In On BeOne Medicines

A number of institutional investors have recently added to or reduced their stakes in ONC. Coldstream Capital Management Inc. bought a new stake in shares of BeOne Medicines during the 3rd quarter worth $201,000. NewEdge Advisors LLC boosted its position in BeOne Medicines by 19.6% during the third quarter. NewEdge Advisors LLC now owns 1,856 shares of the company’s stock valued at $632,000 after buying an additional 304 shares during the period. Voloridge Investment Management LLC bought a new position in shares of BeOne Medicines during the third quarter valued at about $16,270,000. Nomura Holdings Inc. purchased a new position in shares of BeOne Medicines in the third quarter worth about $12,606,000. Finally, Mariner LLC bought a new stake in shares of BeOne Medicines in the 3rd quarter valued at about $290,000. 48.55% of the stock is currently owned by institutional investors and hedge funds.

BeOne Medicines Company Profile

(Get Free Report)